country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Art. -Nr.: HY-184738

Copy Link Print Information

Antifibrotic agent 3

Antifibrotic agent 3 is an orally active antifibrotic agent. Antifibrotic agent 3 reduces hepatic stellate cell activation by downregulating the expression of Collagen I and α-SMA. Antifibrotic agent 3 inhibits liver fibrosis in bile duct ligation and carbon tetrachloride-induced liver fibrosis models. Antifibrotic agent 3 can be used for the research of liver fibrosis.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

CAS. Nr.: 2103516-38-5
Formel: C₁₃H₁₃FN₂O₂
Molecular Weight:248.25

Speicherung:

Please store the product under the recommended conditions in the Certificate of Analysis.

Antifibrotic agent 3 Chemical Structure

CAS. Nr.: 2103516-38-5

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- In Vitro
- In Vivo
Chemical Information
Reinheit & Dokumentation
Verweise
Calculators
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target^[1]

Collagen I

In Vitro

Antifibrotic agent 3 (Compound 5b) (24 h) inhibits TGF-β1-induced activation of CFSC cells by reducing the expression of Collagen I and α-SMA, with no cytotoxicity^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Antifibrotic agent 3 (10 mg/kg; p.o.; once daily; for 14 consecutive days) improves liver function, alleviates pathological liver injury, and suppresses hepatic fibrosis markers in a mouse model of liver fibrosis induced by bile duct ligation (BDL)^[1].
Antifibrotic agent 3 (10 mg/kg; p.o.; once daily; for 14 consecutive days) reduces CCl₄-induced liver injury, collagen deposition, and expression of hepatic fibrosis markers in mice^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

C57BL/6J (male, 6-7 weeks old, 20-22 g, BDL-induced)^[1]
Dosage:

10 mg/kg
Administration:

p.o.; daily; 14 days
Result:

Reduced elevated serum ALT, AST, and AKP levels.
Alleviated liver hardening, rough surface, and yellowish spots.
Reduced inflammatory cell infiltration, hepatocyte edema, and necrosis.
Decreased collagen fiber accumulation.
Lowered hepatic hydroxyproline (HYP) levels.
Reduced liver tissue expression of α-SMA and Collagen I.

Animal Model:

C57BL/6J (male, 6-7 weeks old, 20-22 g, CCl₄-induced)^[1]
Dosage:

10 mg/kg
Administration:

p.o.; daily; 14 days
Result:

Reduced elevated serum ALT and AST levels.
Reduced liver granularity and increased liver glossiness.
Alleviated cellular swelling and inflammatory cell infiltration.
Decreased collagen fiber-stained area.
Lowered hepatic hydroxyproline (HYP) levels.
Reduced liver tissue expression of α-SMA and Collagen I.

Chemical Information

CAS. Nr. 2103516-38-5
Molecular Weight 248.25
Formel C₁₃H₁₃FN₂O₂
SMILES

COC(C1NCCC2=C1NC3=CC(F)=CC=C32)=O
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

Please store the product under the recommended conditions in the Certificate of Analysis.

Reinheit & Dokumentation

Handling Instructions (2659 KB)

Verweise

[1]. Wang C, et al. Discovery of Arenarine D and its active derivatives as a novel lead targeting DYRK1B/MYH9 in hepatic fibrosis. European journal of medicinal chemistry. 2026 Oct 15;316:119063. [Content Brief]

Calculators

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Keywords

MOQ

Minimum order quantity

100 mg

Angebot einholen Auf Lager

Other size

Angebot einholen